Appointments

Request an Appointment

Cancer Answer Line:
866.223.8100

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
3952  Analysis of Human Bone Marrow from Donors Undergoing a Bone Marrow Harvest Main Campus  Aplastic Anemia, Bone Cancer, Bone Marrow Failure, Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML), Leukemia, Chronic Lymphocytic (CLL), Leukemia, Chronic Myeloid (CML), Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Multiple Myeloma, Myelodysplastic Syndrome (MDS)
CASE 491314-147 A Single Arm, Phase II study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients with Acute Myeloid Leukemia undergoing Remission Induction therapy Main Campus Phase 2Leukemia, Acute Myeloid (AML)
CBMT 1911CC00043 (Adult/Pediatric) KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor Main Campus  Blood & Marrow Transplant (BMT), Leukemia, Acute Myeloid (AML)
FHCRC 191314-207 Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study Main Campus Phase 4Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
KALO 1Z1213-595 Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects with EphA3-Expressing Hematologic Malignancies Main Campus Phase 2Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
PFIZ 191213-294 PFIZ 1912 – CC13-294: (B1371003) A phase 1b/2 study to evaluate the safety and efficacy of PF-04449913, an oral hedgehog inhibitor, in combination with intensive chemotherapy, low dose ara-c or decitabine in patients with AML or high-risk MDS Main Campus Phase 1, Phase 2Leukemia, Acute Myeloid (AML), Myelodysplastic Syndrome (MDS)
SEGE 191313-1393 A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia Main Campus Phase 1Leukemia, Acute Myeloid (AML)
SWOG 0919CC777 A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia Main Campus Phase 2Leukemia, Acute Myeloid (AML)
SWOG 120313-415 A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA + V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML) Main Campus Phase 3Leukemia, Acute Myeloid (AML)
SWOG 131213-1292 S1312 testing the addition of Inotuzumab Ozogamicin to usual chemotherapy in relapsed and refractory acute leukemia Main Campus Phase 1Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML)

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.